Early Phase 1
Completed N=8
Ultralow Dose PAH Binary Mixture Study
Environmental Exposure
Source: ClinicalTrials.gov NCT03631667 ↗
Enrolled (actual)
8
Serious AEs
0.0%
Results posted
May 2025
Primary outcomePrimary: Peak Plasma Concentration of 14C-BaP Cmax — 7.07; 1.60 fg [14C]-BaP/mL plasma
Summary
Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Peak Plasma Concentration of 14C-BaP Cmax |
7.07; 1.60 | — |
| PRIMARY Time at Highest Plasma Concentration of 14C-BaP Tmax |
1.1; 1.7 | — |
| SECONDARY Area Under Plasma Concentration of 14C-BaP Versus Time Curve AUC |
17.88; 10.07 | — |
| SECONDARY Rate of Elimination of 14C-BaP (Half Life) |
4.78; 3.92 | — |
Eligibility Criteria
Inclusion Criteria
- Age 21-65 (inclusive)
- If female, must be post-menopausal or have had surgical sterilization to eliminate any possibility for fetal exposure
- Willing to defer blood donation for one month before, throughout, and one month after completion of study activities
- Willing to avoid consuming cruciferous vegetables, I3C or DIM supplements, smoked or cured meat or cheeses, or charcoal-grilled meats for 2 weeks prior to and during each study cycle (gas grilled foods acceptable)
Exclusion Criteria
- Smoker (tobacco or other substances) or use of smokeless tobacco in past 3 months or living with smoker
- Regular use of medications that affect gut motility or nutrient absorption (e.g. cholestyramine, sucralfate, orlistat, pro- or anti-motility agents)
- History of gastrointestinal surgery (e.g. bariatric surgery, cholecystectomy) or gastrointestinal disorder (Crohn's disease, celiac disease, IBS, or colitis)
- Current or history of kidney or liver disease
- Prior high-dose 14C exposure from medical tests. (micro-dose 14C exposure not exclusionary)
- Occupational PAH exposure (e.g. roofers, asphalt pavers, fire-fighters, etc.)
- Regular use of indole-3-carbinol or DIM dietary supplements
Data sourced from ClinicalTrials.gov (NCT03631667). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.